Pro Medicus Limited (ASX: PME.AX) Stock Competitors & Peer Comparison
See PME.AX's competitors and their performance on the ASX and across the wider stock market.
Peer Comparison Table: Medical - Healthcare Information Services Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PME.AX and its ASX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PME.AX | A$160.16 | +0.21% | 16.9B | 72.01 | A$2.25 | +0.38% |
| AYA.AX | A$5.40 | -4.26% | 915.9M | -31.83 | -A$0.18 | N/A |
| CGS.AX | A$2.46 | -2.77% | 421.4M | 26.12 | A$0.09 | +0.81% |
| VHT.AX | A$1.15 | +0.44% | 291.3M | -28.63 | -A$0.04 | N/A |
| ONE.AX | A$0.15 | -11.76% | 140.8M | -7.45 | -A$0.02 | N/A |
| ALC.AX | A$0.09 | -2.25% | 115.5M | 252.94 | A$0.00 | N/A |
| M7T.AX | A$0.30 | +0.00% | 68.2M | -6.88 | -A$0.04 | N/A |
| SHG.AX | A$0.20 | +1.00% | 64.9M | -10.00 | -A$0.02 | N/A |
| BMT.AX | A$0.13 | -7.14% | 40.7M | -6.63 | -A$0.02 | N/A |
| DOC.AX | A$0.12 | +0.00% | 40.3M | -4.58 | -A$0.02 | N/A |
Stock Comparison
Artrya Limited (ASX: AYA.AX)
PME.AX vs AYA.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, AYA.AX has a market cap of 915.9M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while AYA.AX trades at A$5.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas AYA.AX's P/E ratio is -31.83. In terms of profitability, PME.AX's ROE is +0.73%, compared to AYA.AX's ROE of -0.36%. Regarding short-term risk, PME.AX is less volatile compared to AYA.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check AYA.AX's competition here
Cogstate Limited (ASX: CGS.AX)
PME.AX vs CGS.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, CGS.AX has a market cap of 421.4M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while CGS.AX trades at A$2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas CGS.AX's P/E ratio is 26.12. In terms of profitability, PME.AX's ROE is +0.73%, compared to CGS.AX's ROE of +0.22%. Regarding short-term risk, PME.AX is less volatile compared to CGS.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check CGS.AX's competition here
Volpara Health Technologies Limited (ASX: VHT.AX)
PME.AX vs VHT.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, VHT.AX has a market cap of 291.3M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while VHT.AX trades at A$1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas VHT.AX's P/E ratio is -28.63. In terms of profitability, PME.AX's ROE is +0.73%, compared to VHT.AX's ROE of -0.18%. Regarding short-term risk, PME.AX is more volatile compared to VHT.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check VHT.AX's competition here
Oneview Healthcare PLC (ASX: ONE.AX)
PME.AX vs ONE.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, ONE.AX has a market cap of 140.8M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while ONE.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas ONE.AX's P/E ratio is -7.45. In terms of profitability, PME.AX's ROE is +0.73%, compared to ONE.AX's ROE of -2.27%. Regarding short-term risk, PME.AX is less volatile compared to ONE.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check ONE.AX's competition here
Alcidion Group Limited (ASX: ALC.AX)
PME.AX vs ALC.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, ALC.AX has a market cap of 115.5M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while ALC.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas ALC.AX's P/E ratio is 252.94. In terms of profitability, PME.AX's ROE is +0.73%, compared to ALC.AX's ROE of +0.04%. Regarding short-term risk, PME.AX is more volatile compared to ALC.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check ALC.AX's competition here
Mach7 Technologies Limited (ASX: M7T.AX)
PME.AX vs M7T.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, M7T.AX has a market cap of 68.2M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while M7T.AX trades at A$0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas M7T.AX's P/E ratio is -6.88. In terms of profitability, PME.AX's ROE is +0.73%, compared to M7T.AX's ROE of -0.24%. Regarding short-term risk, PME.AX is less volatile compared to M7T.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check M7T.AX's competition here
Singular Health Group Ltd (ASX: SHG.AX)
PME.AX vs SHG.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, SHG.AX has a market cap of 64.9M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while SHG.AX trades at A$0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas SHG.AX's P/E ratio is -10.00. In terms of profitability, PME.AX's ROE is +0.73%, compared to SHG.AX's ROE of -0.60%. Regarding short-term risk, PME.AX is more volatile compared to SHG.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check SHG.AX's competition here
Beamtree Holdings Limited (ASX: BMT.AX)
PME.AX vs BMT.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, BMT.AX has a market cap of 40.7M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while BMT.AX trades at A$0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas BMT.AX's P/E ratio is -6.63. In terms of profitability, PME.AX's ROE is +0.73%, compared to BMT.AX's ROE of -0.14%. Regarding short-term risk, PME.AX is less volatile compared to BMT.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check BMT.AX's competition here
Doctor Care Anywhere Group PLC (ASX: DOC.AX)
PME.AX vs DOC.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, DOC.AX has a market cap of 40.3M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while DOC.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas DOC.AX's P/E ratio is -4.58. In terms of profitability, PME.AX's ROE is +0.73%, compared to DOC.AX's ROE of +2.51%. Regarding short-term risk, PME.AX is less volatile compared to DOC.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check DOC.AX's competition here
Emyria Limited (ASX: EMD.AX)
PME.AX vs EMD.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, EMD.AX has a market cap of 27.5M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while EMD.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas EMD.AX's P/E ratio is -5.95. In terms of profitability, PME.AX's ROE is +0.73%, compared to EMD.AX's ROE of -0.52%. Regarding short-term risk, PME.AX is less volatile compared to EMD.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check EMD.AX's competition here
Corum Group Limited (ASX: COO.AX)
PME.AX vs COO.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, COO.AX has a market cap of 26.3M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while COO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas COO.AX's P/E ratio is N/A. In terms of profitability, PME.AX's ROE is +0.73%, compared to COO.AX's ROE of -0.05%. Regarding short-term risk, PME.AX is more volatile compared to COO.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check COO.AX's competition here
Resonance Health Limited (ASX: RHT.AX)
PME.AX vs RHT.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, RHT.AX has a market cap of 24.8M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while RHT.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas RHT.AX's P/E ratio is 32.70. In terms of profitability, PME.AX's ROE is +0.73%, compared to RHT.AX's ROE of +0.08%. Regarding short-term risk, PME.AX is more volatile compared to RHT.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check RHT.AX's competition here
PainChek Limited (ASX: PCK.AX)
PME.AX vs PCK.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, PCK.AX has a market cap of 24M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while PCK.AX trades at A$0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas PCK.AX's P/E ratio is -4.60. In terms of profitability, PME.AX's ROE is +0.73%, compared to PCK.AX's ROE of -10.10%. Regarding short-term risk, PME.AX is more volatile compared to PCK.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check PCK.AX's competition here
TrivarX Limited (ASX: TRI.AX)
PME.AX vs TRI.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, TRI.AX has a market cap of 19.6M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while TRI.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas TRI.AX's P/E ratio is N/A. In terms of profitability, PME.AX's ROE is +0.73%, compared to TRI.AX's ROE of -0.12%. Regarding short-term risk, PME.AX is less volatile compared to TRI.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check TRI.AX's competition here
Vitasora Health Limited (ASX: VHL.AX)
PME.AX vs VHL.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, VHL.AX has a market cap of 16.7M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while VHL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas VHL.AX's P/E ratio is -0.75. In terms of profitability, PME.AX's ROE is +0.73%, compared to VHL.AX's ROE of -4.12%. Regarding short-term risk, PME.AX is less volatile compared to VHL.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check VHL.AX's competition here
ImExHS Limited (ASX: IME.AX)
PME.AX vs IME.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, IME.AX has a market cap of 16.6M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while IME.AX trades at A$0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas IME.AX's P/E ratio is -3.97. In terms of profitability, PME.AX's ROE is +0.73%, compared to IME.AX's ROE of -0.19%. Regarding short-term risk, PME.AX is less volatile compared to IME.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check IME.AX's competition here
1st Group Limited (ASX: 1ST.AX)
PME.AX vs 1ST.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, 1ST.AX has a market cap of 15.6M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while 1ST.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas 1ST.AX's P/E ratio is -1.10. In terms of profitability, PME.AX's ROE is +0.73%, compared to 1ST.AX's ROE of +0.69%. Regarding short-term risk, PME.AX is more volatile compared to 1ST.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check 1ST.AX's competition here
MedAdvisor Limited (ASX: MDR.AX)
PME.AX vs MDR.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, MDR.AX has a market cap of 14M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while MDR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas MDR.AX's P/E ratio is -0.20. In terms of profitability, PME.AX's ROE is +0.73%, compared to MDR.AX's ROE of -2.41%. Regarding short-term risk, PME.AX is less volatile compared to MDR.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check MDR.AX's competition here
Adheris Health Limited (ASX: AHE.AX)
PME.AX vs AHE.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, AHE.AX has a market cap of 11.5M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while AHE.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas AHE.AX's P/E ratio is 1.61. In terms of profitability, PME.AX's ROE is +0.73%, compared to AHE.AX's ROE of -15.67%. Regarding short-term risk, PME.AX is less volatile compared to AHE.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check AHE.AX's competition here
Pathkey.AI Ltd (ASX: PKY.AX)
PME.AX vs PKY.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, PKY.AX has a market cap of 11M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while PKY.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas PKY.AX's P/E ratio is -4.92. In terms of profitability, PME.AX's ROE is +0.73%, compared to PKY.AX's ROE of -11.22%. Regarding short-term risk, PME.AX is less volatile compared to PKY.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check PKY.AX's competition here
Intelicare Holdings Limited (ASX: ICR.AX)
PME.AX vs ICR.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, ICR.AX has a market cap of 8.5M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while ICR.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas ICR.AX's P/E ratio is -3.32. In terms of profitability, PME.AX's ROE is +0.73%, compared to ICR.AX's ROE of +5.38%. Regarding short-term risk, PME.AX is more volatile compared to ICR.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check ICR.AX's competition here
Enlitic, Inc. (ASX: ENL.AX)
PME.AX vs ENL.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, ENL.AX has a market cap of 5.8M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while ENL.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas ENL.AX's P/E ratio is -0.23. In terms of profitability, PME.AX's ROE is +0.73%, compared to ENL.AX's ROE of -1.39%. Regarding short-term risk, PME.AX is more volatile compared to ENL.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check ENL.AX's competition here
Opyl Limited (ASX: OPL.AX)
PME.AX vs OPL.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, OPL.AX has a market cap of 5.4M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while OPL.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas OPL.AX's P/E ratio is -2.20. In terms of profitability, PME.AX's ROE is +0.73%, compared to OPL.AX's ROE of +12.68%. Regarding short-term risk, PME.AX is more volatile compared to OPL.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check OPL.AX's competition here
Visionflex Fpo [vfx] (ASX: VFX.AX)
PME.AX vs VFX.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, VFX.AX has a market cap of 5M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while VFX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas VFX.AX's P/E ratio is -2.90. In terms of profitability, PME.AX's ROE is +0.73%, compared to VFX.AX's ROE of +1.57%. Regarding short-term risk, PME.AX is less volatile compared to VFX.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check VFX.AX's competition here
Medibio Limited (ASX: MEB.AX)
PME.AX vs MEB.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, MEB.AX has a market cap of 4.5M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while MEB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas MEB.AX's P/E ratio is -0.10. In terms of profitability, PME.AX's ROE is +0.73%, compared to MEB.AX's ROE of -0.15%. Regarding short-term risk, PME.AX is less volatile compared to MEB.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check MEB.AX's competition here
HITIQ Limited (ASX: HIQ.AX)
PME.AX vs HIQ.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, HIQ.AX has a market cap of 4M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while HIQ.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas HIQ.AX's P/E ratio is -0.59. In terms of profitability, PME.AX's ROE is +0.73%, compared to HIQ.AX's ROE of +1.53%. Regarding short-term risk, PME.AX is more volatile compared to HIQ.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check HIQ.AX's competition here
TALi Digital Limited (ASX: TD1.AX)
PME.AX vs TD1.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, TD1.AX has a market cap of 3.7M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while TD1.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas TD1.AX's P/E ratio is -3.27. In terms of profitability, PME.AX's ROE is +0.73%, compared to TD1.AX's ROE of -0.42%. Regarding short-term risk, PME.AX is less volatile compared to TD1.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check TD1.AX's competition here
Careteq Limited (ASX: CTQ.AX)
PME.AX vs CTQ.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, CTQ.AX has a market cap of 2.9M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while CTQ.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas CTQ.AX's P/E ratio is -13.33. In terms of profitability, PME.AX's ROE is +0.73%, compared to CTQ.AX's ROE of -0.14%. Regarding short-term risk, PME.AX is more volatile compared to CTQ.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check CTQ.AX's competition here
Oakridge International Limited (ASX: OAK.AX)
PME.AX vs OAK.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, OAK.AX has a market cap of 2.1M. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while OAK.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas OAK.AX's P/E ratio is N/A. In terms of profitability, PME.AX's ROE is +0.73%, compared to OAK.AX's ROE of +0.17%. Regarding short-term risk, PME.AX is less volatile compared to OAK.AX. This indicates lower risk in terms of short-term price fluctuations for PME.AX.Check OAK.AX's competition here
Jayex Technology Limited (ASX: JTL.AX)
PME.AX vs JTL.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, JTL.AX has a market cap of 281.3K. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while JTL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas JTL.AX's P/E ratio is -0.10. In terms of profitability, PME.AX's ROE is +0.73%, compared to JTL.AX's ROE of +0.60%. Regarding short-term risk, PME.AX is more volatile compared to JTL.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check JTL.AX's competition here
Total Brain Limited (ASX: TTB.AX)
PME.AX vs TTB.AX Comparison July 2026
Pro Medicus Limited (ASX: PME.AX) plays a significant role within the Healthcare sector. Its performance on the ASX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PME.AX stands at 16.9B. In comparison, TTB.AX has a market cap of 267.4K. Regarding current trading prices, PME.AX is priced at A$160.16 on the ASX, while TTB.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PME.AX currently has a P/E ratio of 72.01, whereas TTB.AX's P/E ratio is -0.02. In terms of profitability, PME.AX's ROE is +0.73%, compared to TTB.AX's ROE of -1.05%. Regarding short-term risk, PME.AX is more volatile compared to TTB.AX. This indicates higher risk in terms of short-term price fluctuations for PME.AX.Check TTB.AX's competition here